SynthesisBMC gastroenterology2025
Quantitative literature analysis on efficacy and safety of balloon-occluded transarterial chemoembolization for hepatocellular carcinoma.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Balloon-Occluded Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma.The Indian journal of radiology & imaging · 2026Article
- From Flow Modulation to Resection: First in Human Combination of Liver Venous Deprivation and Balloon-Occluded Chemoembolization (LVD-B-TACE): A Case Report Demonstrating a Novel Sequential Concept.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo analyze the efficacy and safety of balloon-occluded transarterial chemoembolization (B-TACE) of hepatocellular carcinoma (HCC).
methodsWe searched English databases, assessed the quality of the selected studies, analyzed the extracted data, tested heterogeneity of data, explored the resources of heterogeneity, and tested publication bias.
resultsAfter inclusion and exclusion criterion, totally 7 studies included in our analysis. The numbers of complete response (CR) in B-TACE were significantly more than in Non B-TACE (P = 0.003). There were no significant difference in partial response (PR), stable disease (SD) and progressive disease (PD) between B-TACE and Non B-TACE. Moderate heterogeneity existed in CR and PR (I
conclusionB-TACE was safe. It showed promising efficacy in achieving higher CR rates in short term compared to Non B-TACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.